Rating Rationale
March 13, 2020 | Mumbai
SJS Healthcare Limited
Rating outlook revised to 'Stable'; ratings reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.50 Crore
Long Term Rating CRISIL BBB/Stable (Outlook revised from 'Positive' and rating reaffirmed)
Short Term Rating CRISIL A3+ (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has revised its outlook on the long-term bank facilities of SJS Healthcare Limited (SJS) to 'Stable' from 'Positive' and has reaffirmed the rating at 'CRISIL BBB'. The short term rating has been reaffirmed at 'CRISIL A3+' .
 
The revision in outlook reflects CRISIL's belief that the company's liquidity profile will be impacted on account of sizeable loans being contracted, for investing in its group entity Namdhari Agro Fresh Pvt Ltd (NAFPL). As a result, though the accrual is expected to remain sufficient for the upcoming debt repayment, the cushion between accrual and debt repayment would be moderated, which is against CRISIL's previous expectations. Also, with contraction of the discussed debt, the capital structure and debt protection metrics would also be impacted.

The ratings continue to reflect the company's established regional market position in the healthcare industry and a healthy financial risk profile. These strengths are partially offset by moderate scale of operations amid exposure to intense competition and sizeable investments in the group entity.

Key Rating Drivers & Detailed Description
Strengths:
* Established regional market position in the healthcare industry: The company has had a presence of around 15 years in the healthcare industry. It runs SPS Hospital, which provides tertiary healthcare services in multi-specialty areas such as cardiology, neurology, and gynaecology in Ludhiana, Punjab. Accreditation by the Joint Commission International (JCI) for four times in such a short span, further strengthens the market position. Additionally, by running its own pharmacy and inclusion of visa medical services, the market position has further strengthened in the past few years, as reflected in estimated compound annual growth rate of 15% in revenue in the four fiscals through 2020.
 
* Healthy financial risk profile: With contraction of term debt (for investing in its group entity), the financial risk profile shall remain slightly impacted, but will continue to remain robust. Despite slight increase expected over the medium term, the total outside liabilities to tangible networth ratio shall remain healthy, at below 1 time, predominantly supported by strong networth. Additionally, with incremental interest obligation, debt protection metrics shall moderate slightly, however, will continue to remain healthy; interest coverage and net cash accrual to debt ratios are expected to be around 5 times and 0.5 time, respectively, in the current fiscal.
 
Weaknesses:
* Moderate scale amid exposure to intense competition: Although, starting its own pharmacy and visa medical services have benefitted the company, the estimated revenue of Rs 160 crore during April to January in fiscal 2020, is modest. The scale is constrained on account of high geographical concentration, and competition from other large hospitals in the vicinity, such as Fortis Hospital, Dayanand Medical College & Hospital, and Christian Medical College.
 
* Sizeable investment in group entity: SJS shall be investing Rs 45-50 crore in the business expansion of one of its group companies, NAFPL, out of which around Rs 15 crore has already been invested. As a result, SJS's financial risk profile, particularly liquidity, would be impacted as investments would be funded entirely through contraction of outside debt. Although, net cash accrual to total debt ratio shall remain comfortable over the next few years, it is expected to decline to 3.5-4 times from over 10 times historically. Quantum of further investment over the medium term (if exist), will remain a key monitorable
Liquidity Adequate

Liquidity is supported by comfortable accrual against maturing debt, low bank limit utilisation, and prudent working capital management. However, it is partly constrained on account of sizeable investments in its group entity. SJS proposes to invest close to Rs 50 crore in its group entity, which would be funded by raising external debt, hence leveraging its liquidity profile. As a result, the net cash accrual to total debt ratio, expected at 3.5-4 times, would be significantly lower than the historical trend of over 10 times. However, liquidity is supported by low bank limit utilisation, averaging 48% for the 12 months through December 2019. Positive cash flow from operations is expected to aid the incremental working capital requirement, over the medium term.

Outlook: Stable

CRISIL believes SJS will continue to benefit, over the medium term, from its established market position and healthy financial risk profile.
 
Rating sensitivity factors
Upward factors
* Sustained increase in revenue and profitability, leading to annual accrual of over Rs 35 crore
* Efficient working capital management
 
Downward factors
* Further investment in group entities
* Lower revenue or profitability leading to annual accrual of below Rs 20 crore
* Stretched working capital cycle or sizeable debt-funded capital expenditure, impacting the financial risk profile

About the Company

Set up in 1999 by Satguru Uday Singh (current guru of Namdhari Sikhs), SJS runs a multi-specialty hospital, SPS Hospitals (Satguru Pratap Singh Healthcare) in Ludhiana, Punjab, that provides tertiary healthcare services in cardiology, neurology, and gynaecology.

Key Financial Indicators
As on/for the period ended March 31 Unit  2019 2018
Operating income Rs crore 182.7 150.45
Reported profit after tax (PAT) Rs crore 16.6 -1.8
PAT margin % 9.08 -1.19
Adjusted debt/adjusted networth Times 0.37 0.57
Interest coverage Times 10.74 6.61
Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon rate (%) Maturity date Issue size
(Rs crore)
Rating assigned
with outlook
NA Overdraft NA NA NA 25.0 CRISIL A3+
NA Long Term Loan NA NA Mar-2025 20.0 CRISIL BBB/stable
NA Proposed Long Term Bank Loan Facility NA NA NA 5.0 CRISIL BBB/stable
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  50.00  CRISIL BBB/Stable/ CRISIL A3+      31-01-19  CRISIL BBB/Positive/ CRISIL A3+      13-10-17  CRISIL BBB/Stable/ CRISIL A3+  CRISIL BBB-/Stable/ CRISIL A3 
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Long Term Loan 20 CRISIL BBB/Stable Long Term Loan 9 CRISIL BBB/Positive
Overdraft 25 CRISIL A3+ Overdraft 25 CRISIL A3+
Proposed Long Term Bank Loan Facility 5 CRISIL BBB/Stable Proposed Long Term Bank Loan Facility 16 CRISIL BBB/Positive
Total 50 -- Total 50 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Nitin Kansal
Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2154
nitin.kansal@crisil.com


Gaurav Arora
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2181
Gaurav.Arora@crisil.com


Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL